… in human kidney cancer increase mTOR kinase activity in a … include programmed-death 1
(PD-1) and cytotoxic T-lymphocyte… an increase in toxicity. These limitations in the use of current …

… /PD-L1 therapy was reported to impair Treg cells in the renal … sustained anti-tumor efficacy
while promoting allograft tolerance … (PD-1, TIM3) prior to SARS-CoV-2 infection at the time of …

… inhibitors mitigate the risk of rejection through uncoupling of the efficacy and toxicity of …
Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal …

… that mTOR inhibitors had the potential to uncouple the efficacy and rejection of ICIs in renal
… to allograft rejection than PD-1 blockade (preventing the interactions of PD-1 with PD-L1 and …

… Herein, we summarized the efficiency and side effects based … It was reported that blocking
the PD-1 pathway could reduce … role in renal allograft rejection on anti-PD-1 therapy (99). After …

… Caloric restriction mimetics are non-toxic compounds able to … immune checkpoint inhibitors
targeting PD-1. Collectively, … approach to melanoma and metastatic renal cell carcinoma [287]…

… In this review, we summarize current knowledge on the mechanisms of PD-1, CTLA-4, and
… new target for reduction of anti-PD-1 induced toxicity, while maintaining anti-tumor efficacy. …

… using monoclonal antibodies that target PD-1/PD-L1. … as transplantation failure, renal function
decline requiring dialysis… long as clinical benefits are observed and toxicity does not occur. …

… Again mTOR pathway regulates the biological effects of immune cell stimulation. AKT/PI3K …
The efficiency and toxicity of CTLA-4-targeting antibodies can potentially be separated using …

… between treatment risks (toxicities) and benefits (efficacy), as … and 29 patients receiving
kidney transplant were treated with … Safety and efficacy of anti-PD-1/anti-PD-L1 therapy in cancer …